




Baseline Procedures: Consenting and Enrolling Patients

emphasis.core.ubc.ca

Click for more information

1




To review how to recruit and screen a potential study participant,
please see the previous mini-webinar on:
"Baseline Procedures: Recruiting and Screening Patients"

Once you have identified a study participant who is willing to participate in the study and fulfills in the inclusion criteria, you are now ready to start obtaining consent and officially enrolling the patient into the study!

2

For Eligible Patients



In your binder

- 10 Enrolment Packages (in plastic covers)

[Instructions](#)

[Subject Information and Consent Form](#)

[Contact Form](#)

[Demographic Form](#)

[Participant Guide](#)

[Magnet – Intervention Group only]

- Use 1 package per eligible patient

3

1. Consent Eligible Patients

- Important part of enrollment process
- Review **Subject Information and Consent Form** with patient

- Have patient sign the 2 copies of page 9
 - 1 copy stapled to form → Patient takes home
 - 1 copy not stapled → Fax to UBC and File in binder

- **AFTER** the patient has signed the consent form, you may inform him/her of the study group assignment

4

2. Complete Enrolment

Complete Contact and Demographics forms

- Have patient complete
 - [Contact Form](#)
 - [Demographic Form](#)

5

2. Complete Enrolment

Please stick the Patient **Study ID** sticker onto the form

Contact Information Form
For Pharmacy Use Only

Please answer the following:

First Name: _____ Last Name: _____
 Street Address: _____
 City: _____ Province: _____ Postal Code: _____
 Telephone: _____ Fax: _____
 Email: _____

Please have your patient complete the following questions:

Are you a pharmacist? ☐ Yes ☐ No
 Are you a pharmacist? ☐ Yes ☐ No
 Are you a pharmacist? ☐ Yes ☐ No
 Are you a pharmacist? ☐ Yes ☐ No

Signature of Pharmacist: _____ Date: _____

Signature of Patient: _____ Date: _____

Signature of Pharmacist: _____ Date: _____

Signature of Patient: _____ Date: _____

Patients can complete the contact form themselves, but **verify** that **ALL FIELDS** are completed!

6

A diagram illustrating the addition of two objects. The top row shows a small figure holding a red balloon and a small figure holding a blue balloon, with a plus sign between them. The bottom row shows a single small figure holding both a red and a blue balloon.

- Fax to UBC **604-827-4014**
- File in your binder (“Completed Forms” tab)
- **Update the Study Log**
 - Found at the front of your binder

The screenshot shows a Microsoft Word document with a table. The table has 4 columns and 4 rows. The first column contains text, while the other three columns are empty. The text in the first column is partially obscured by a watermark.

Fax the **Physician Letter** to physicians in your community

THE UNIVERSITY OF BRISTOL CULIMA

UNIVERSITY OF BRISTOL

SCHOOL OF MEDICINE

FACULTY OF PHARMACEUTICAL SCIENCES

UNIVERSITY OF BRISTOL

SCHOOL OF MEDICINE

FACULTY OF PHARMACEUTICAL SCIENCES

Invitation

Invitation

Dear Dr. **_____**

On behalf of the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

and the **_____** (UK)

Dear Dr.

The purpose of this letter is to inform you of a new study being initiated in your community entitled **EnPaaS[®] Empowering**

this study is conducted at **UHC[®] Faculty of Pharmaceutical Sciences** in collaboration with **UHC[®] Faculty of Medicine**.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

The **EnPaaS[®]** study is designed to assess whether a pharmacological substance that you are managing your asthma medication will help improve adherence to the medication and their outcomes.

**Maya De Vries, PhD,
Principal Investigator**

<

11



12